MARKET

BEAM

BEAM

BEAM THERAPEUTICS INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

60.06
+1.58
+2.70%
After Hours: 60.25 +0.19 +0.32% 16:56 12/04 EST
OPEN
58.99
PREV CLOSE
58.48
HIGH
61.11
LOW
57.59
VOLUME
773.68K
TURNOVER
--
52 WEEK HIGH
61.11
52 WEEK LOW
13.00
MARKET CAP
3.48B
P/E (TTM)
-19.3779
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020
GlobeNewswire · 3h ago
The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 3)
Benzinga · 1d ago
The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2)
Benzinga · 2d ago
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 1)
Benzinga · 3d ago
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 11/24 13:12
The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020
GlobeNewswire · 11/20 21:01
The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020
Beam TherapeuticsInc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named one of the Top Places to Work in Massachusetts in the 13th annual employee-based survey project from The Boston Globe for the second year in a row. Top Places to Work recognizes the most admired workplaces in the state voted on by the people who know them best: their employees. The survey measures employee opinions about their company's direction, execution, connection, management, work, pay and benefits, and engagement.
GlobeNewswire · 11/20 21:01
Beam Therapeutics Reports Will Present First Data Highlighting Base Editing Program For Glycogen Storage Disease Type Ia At American Association for the Study of Liver Diseases Nov. 14
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present preclinical data from its liver-focused programs,
Benzinga · 11/13 13:06
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BEAM. Analyze the recent business situations of BEAM THERAPEUTICS INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BEAM stock price target is 43.00 with a high estimate of 47.00 and a low estimate of 38.00.
EPS
Institutional Holdings
Institutions: 100
Institutional Holdings: 28.98M
% Owned: 50.00%
Shares Outstanding: 57.97M
TypeInstitutionsShares
Increased
32
3.85M
New
33
-1.14M
Decreased
9
886.05K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
President/Chief Scientific Officer
Giuseppe Ciaramella
Chief Executive Officer/Director
John Evans
Co-Founder
J. Keith Joung
Co-Founder
David Liu
Chief Financial Officer/Treasurer
Terry-Ann Burrell
Senior Vice President
Manmohan Singh
Senior Vice President
Christine Swenson
Independent Director
Kristina Burow
Independent Director
Graham Cooper
Independent Director
Mark Fishman
Independent Director
Carole Ho
Independent Director
Stephen Knight
Independent Director
Robert Nelsen
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BEAM
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). It is advancing a broad, diversified portfolio of 12 base editing programs against distinct editing targets. Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Beam Therapeutics Inc stock information, including NASDAQ:BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.